Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.

Human immunodeficiency virus (HIV) encodes an aspartic protease (PR) that cleaves viral polyproteins into mature proteins, thus leading to the formation of infectious particles. Protease inhibitors (PIs) are successful virostatics. However, their efficiency is compromised by antiviral resistance. In the PR sequence of viral variants resistant to the PI nelfinavir, the mutations D30N and L90M appear frequently. However, these two mutations are seldom found together in vivo, suggesting that there are two alternative evolutionary pathways leading to nelfinavir resistance. Here we analyze the proteolytic activities, X-ray structures, and thermodynamics of inhibitor binding to HIV-1 PRs harboring the D30N and L90M mutations alone and in combination with other compensatory mutations. Vitality values obtained for recombinant mutant proteases and selected PR inhibitors confirm the crucial role of mutations in positions 30 and 90 for nelfinavir resistance. The combination of the D30N and L90M mutations significantly increases the enzyme vitality in the presence of nelfinavir, without a dramatic decrease in the catalytic efficiency of the recombinant enzyme. Crystal structures, molecular dynamics simulations, and calorimetric data for four mutants (D30N, D30N/A71V, D30N/N88D, and D30N/L90M) were used to augment our kinetic data. Calorimetric analysis revealed that the entropic contribution to the mutant PR/nelfinavir interaction is less favorable than the entropic contribution to the binding of nelfinavir by wild-type PR. This finding is supported by the structural data and simulations; nelfinavir binds most strongly to the wild-type protease, which has the lowest number of protein-ligand hydrogen bonds and whose structure exhibits the greatest degree of fluctuation upon inhibitor binding.

[1]  J. Louis,et al.  Structural implications of drug‐resistant mutants of HIV‐1 protease: High‐resolution crystal structures of the mutant protease/substrate analogue complexes , 2001, Proteins.

[2]  Maureen M Goodenow,et al.  Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease. , 2004, Biochemistry.

[3]  Florian Weigend,et al.  Auxiliary basis sets for main row atoms and transition metals and their use to approximate Coulomb potentials , 1997 .

[4]  R. Shafer,et al.  N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. , 2006, AIDS research and human retroviruses.

[5]  Masayuki Hata,et al.  Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. , 2005 .

[6]  R M Stroud,et al.  Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. , 1998, Biochemistry.

[7]  Thomas Klimkait,et al.  Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. , 2002, Journal of molecular biology.

[8]  M. Sternberg,et al.  An analysis of conformational changes on protein-protein association: implications for predictive docking. , 1999, Protein engineering.

[9]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Martyn D Winn,et al.  Macromolecular TLS refinement in REFMAC at moderate resolutions. , 2003, Methods in enzymology.

[11]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[12]  Heinrich Sticht,et al.  Molecular Dynamics Simulations of HIV-1 Protease Suggest Different Mechanisms Contributing to Drug Resistance. , 2005, Journal of chemical theory and computation.

[13]  J. Konvalinka,et al.  Systematic mutational analysis of the active‐site threonine of HIV‐1 proteinase: Rethinking the “fireman's grip” hypothesis , 2000, Protein science : a publication of the Protein Society.

[14]  W. Farmerie,et al.  Sensitive, soluble chromogenic substrates for HIV-1 proteinase. , 1990, The Journal of biological chemistry.

[15]  I. Pichová,et al.  Configurations of diastereomeric hydroxyethylene isosteres strongly affect biological activities of a series of specific inhibitors of human-immunodeficiency-virus proteinase. , 1997, European journal of biochemistry.

[16]  Hans W. Horn,et al.  ELECTRONIC STRUCTURE CALCULATIONS ON WORKSTATION COMPUTERS: THE PROGRAM SYSTEM TURBOMOLE , 1989 .

[17]  Ursula Rothlisberger,et al.  Drug resistance in HIV‐1 protease: Flexibility‐assisted mechanism of compensatory mutations , 2002, Protein science : a publication of the Protein Society.

[18]  Burke,et al.  Generalized Gradient Approximation Made Simple. , 1996, Physical review letters.

[19]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[20]  I. Wilson,et al.  Applications of the streak seeding technique in protein crystallization , 1991 .

[21]  L. Lally.  The CCP 4 Suite — Computer programs for protein crystallography , 1998 .

[22]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[23]  J. Morrison,et al.  [17] The kinetics of reversible tight-binding inhibition , 1979 .

[24]  W. Guida,et al.  Accurate Prediction of Acidity Constants in Aqueous Solution via Density Functional Theory and Self-Consistent Reaction Field Methods , 2002 .

[25]  F. Weigend,et al.  Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: Design and assessment of accuracy. , 2005, Physical chemistry chemical physics : PCCP.

[26]  J F Morrison,et al.  The kinetics of reversible tight-binding inhibition. , 1979, Methods in enzymology.

[27]  Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease. , 2004 .

[28]  Maureen M Goodenow,et al.  Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. , 2003, Biochemistry.

[29]  F. Mammano,et al.  Parameters Driving the Selection of Nelfinavir-Resistant Human Immunodeficiency Virus Type 1 Variants , 2003, Journal of Virology.

[30]  D. R. Kuritzkes,et al.  Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.

[31]  M. Summers,et al.  Structural biology of HIV. , 1999, Journal of molecular biology.

[32]  J F Davies,et al.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.

[33]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[34]  G. Eichele,et al.  Repeated seeding technique for growing large single crystals of proteins. , 1981, Journal of molecular biology.

[35]  Celia A Schiffer,et al.  Design of HIV-1 protease inhibitors active on multidrug-resistant virus. , 2005, Journal of medicinal chemistry.

[36]  G. Plosker,et al.  Nelfinavir , 2000, Drugs.

[37]  J. Konvalinka,et al.  Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex. , 2004, Acta crystallographica. Section D, Biological crystallography.

[38]  J. Konvalinka,et al.  Characterisation of mutated proteinases derived from hiv-positive patients: Enzyme activity, vitality and inhibition , 2004 .

[39]  A. Velázquez‐Campoy,et al.  Overcoming drug resistance in HIV‐1 chemotherapy: The binding thermodynamics of Amprenavir and TMC‐126 to wild‐type and drug‐resistant mutants of the HIV‐1 protease , 2002, Protein science : a publication of the Protein Society.

[40]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[41]  Irene T Weber,et al.  Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. , 2004, European journal of biochemistry.

[42]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[43]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[44]  A. Klamt,et al.  COSMO : a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient , 1993 .

[45]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[46]  B. Honig,et al.  Calculation of the total electrostatic energy of a macromolecular system: Solvation energies, binding energies, and conformational analysis , 1988, Proteins.

[47]  J. Louis,et al.  Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. , 2000, European journal of biochemistry.

[48]  E. Freire,et al.  Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. , 2003, Biochemistry.

[49]  Brendan Larder,et al.  Interference between D30N and L90M in Selection and Development of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1 , 2002, Antimicrobial Agents and Chemotherapy.